Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

SELL
$0.2 - $0.5 $171,396 - $428,491
-856,983 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$0.41 - $0.63 $351,363 - $539,899
856,983 New
856,983 $471,000
Q4 2019

Feb 12, 2020

SELL
$0.62 - $1.06 $69,612 - $119,015
-112,279 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$0.81 - $1.06 $90,945 - $119,015
112,279 New
112,279 $109,000
Q4 2018

Feb 12, 2019

SELL
$0.39 - $3.47 $105,396 - $937,757
-270,247 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$1.39 - $2.25 $113,423 - $183,600
-81,600 Reduced 23.19%
270,247 $573,000
Q2 2018

Aug 09, 2018

BUY
$1.44 - $2.24 $329,616 - $512,736
228,900 Added 186.18%
351,847 $507,000
Q1 2018

May 11, 2018

SELL
$1.51 - $2.06 $40,770 - $55,620
-27,000 Reduced 18.01%
122,947 $202,000
Q4 2017

Feb 14, 2018

BUY
$1.4 - $2.6 $81,760 - $151,840
58,400 Added 63.79%
149,947 $240,000
Q3 2017

Nov 20, 2017

BUY
$2.22 - $2.79 $203,234 - $255,416
91,547
91,547 $233,000

About TREVENA INC


  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.